Many anti-obesity agents such as liraglutide, curcumin and berberine have been shown to enhance energy expenditure. Multiple studies have proved that increasing energy expenditure is an effective way to prevent obesity.
Interestingly, oral administration of asperlin did not decrease food intake, suggesting that asperlin exerts its obesity-preventing effect through other ways, rather than food restriction. These results indicate that asperlin possesses adequate anti-obesity effects. Hyperglycemia was also ameliorated, though the alleviation did not reach statistical significance. The serum and/or liver levels of TC, TG and LDL-c and fat vacuole formation in hepatocytes were substantially reversed by asperlin. Simultaneously, asperlin noticably ameliorated hyperlipidemia and liver steatosis. These effects were similar to those elicited by the approved anti-obesity drug, orlistat, as well as natural products such as cordycepin and berberine, demonstrating potent activity against HFD-induced obesity. First, oral administration of asperlin for 12 weeks significantly prevented bodyweight gain, decreased fat deposit, and reduced body fat rate and Lee’s index. In this study, we demonstrated for the first time that asperlin prevented HFD-induced obesity and alleviated hyperlipidemia. Its anti-obesity properties may be attributed to its effect on promoting energy expenditure.Īsperlin is a marine-derived fungal product possessing multiple properties such as antitumor, anti-inflammation and anti-atherosclerosis. These results demonstrated that asperlin is effective in preventing HFD-induced obesity and modulating gut microbiota. The HFD-induced abnormalities at both phylum and genus levels were all remarkably recovered by asperlin. Oral administration of asperlin markedly increased the relative abundance of Bacteroidetes, leading to a higher Bacteroidetes-to-Fimicutes ratio. Meanwhile, asperlin also increased the diversity and shifted the structure of gut microbiota. Accordingly, asperlin-treated mice showed higher body temperature and were more tolerant of cold stress.
A respiratory metabolism monitor showed that asperlin efficiently increased energy expenditure and enhanced thermogenic gene expression in adipose tissue. Hyperlipidemia and liver steatosis were also substantially ameliorated. Oral administration of asperlin for 12 weeks significantly suppressed HFD-induced body weight gain and fat deposition without inhibiting food intake. In the present study, we showed that asperlin effectively prevented the development of obesity in high-fat diet (HFD)-fed mice. Asperlin is a marine-derived, natural product with antifungal, anti-inflammatory and anti-atherosclerotic activities.
0 kommentar(er)
